OBT076 not checked
Oxford BioTherapeutics Ltd · MEN1309
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Solid Tumor
- Main trialPhase 1
- “The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the…”In the company’s words, NCT04064359 on ClinicalTrials.gov
- Other names
- MEN1309
Other drugs for Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- 31 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 10 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT04064359
- 10 NovCompletion date moved: 2026-12-31 to 2027-12-31 · ClinicalTrials.gov NCT04064359
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 31 Dec 2027 | Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026